

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-32444A
APPLICATION NO.
10/510,026
APPLICANT
COPPOLA ET AL.
FILING DATE
OCTOBER 1, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
NG	AA	5,958,957	9/28/99	Anderson et al.	514	364	4/16/97
NG	AB	5,972,978	10/26/99	Anderson et al.	514	361	2/19/99
NG	AC	6,063,800	5/16/00	Anderson et al.	514	369	2/19/99
NG	AD	6,080,770	6/27/00	Anderson et al.	514	359	2/19/99
NG	AE	5,162,340	11/10/92	Chakravarty et al.	514	309	5/10/91
NG	AF	5,281,614	1/25/94	Ashton et al.	514	359	11/2/92
NG	AG	5,412,097	5/2/95	Chakravarty et al.	546	118	9/2/92
NG	AH	5,972,978	10/26/99	Andersen et al.	514	361	2/19/99
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
*	NG	AJ	WO 97/40017	10/30/97	PCT		<input type="checkbox"/>	<input type="checkbox"/>
*	NG	AK	WO 01/19831	3/22/01	PCT		<input type="checkbox"/>	<input type="checkbox"/>
	NG	AL	0 512 870	11/11/92	EP		<input type="checkbox"/>	<input type="checkbox"/>
	NG	AM	WO 92/20687	11/26/92	PCT		<input type="checkbox"/>	<input type="checkbox"/>
		AN					<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

NG	AO	Albericio et al., "Synthesis of a Sulfahydantoin Library", J. Comb. Chem. Vol. 3, pp 290-300 (2001)						
*	NG	AP	Bright et al., "Competitive particle concentration fluorescence immunoassays for measuring antidiabetic drug levels in mouse plasma" Journal of Immunological Methods, vol. 207, pages 23-31(1997).					
	NG	AQ	Abstract, Eberle et al., "Preparation of microbiocidal N-phenyl-N [4- (-pyridyl)-pyrimidin-2-yl) amines					
	NG	AR	Ducry et al., "Synthesis of 1,2,5-Thiadiazolidin-3-one 1,1-Dioxide Derivatives and evaluation of their affinity for MHC Class-II Proteins", Helvetica Chimica, Acta, Vol. 82, No. 12, pp. 2432-2447 (1999)					
*	NG	AS	Mantegani et al., "Synthesis and Antihypertensive Activity of 2,4-dioximidazolidin-1-yl and perhydro-2,4-dioxypyrimidin-1-yl ergoline derivatives", IL FARMACO, vol. 53, pp 293-304 (1998)					
EXAMINER		/Nyeemah Grazier/			DATE CONSIDERED		12/21/2006	

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.